According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:
1. Embecta (NASDAQ:EMBC)
Embecta (NASDAQ:EMBC) is the #1 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: C.
Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 10 points higher than the healthcare sector average of 25. It passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -8.73% over the past year, overperforming other healthcare stocks by 32 percentage points.
Embecta has an average 1 year
price target of $18.50, an upside of 22.84% from Embecta's current stock price of $15.06.
Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Livanova (NASDAQ:LIVN)
Livanova (NASDAQ:LIVN) is the #2 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Livanova (NASDAQ:LIVN) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: A.
Livanova (NASDAQ:LIVN) has a Due Diligence Score of 17, which is -8 points lower than the healthcare sector average of 25. Although this number is below the industry average, our proven quant model rates LIVN as a "A".It passed 5 out of 33 due diligence checks and has weak fundamentals. Livanova has seen its stock return 6.92% over the past year, overperforming other healthcare stocks by 48 percentage points.
Livanova has an average 1 year
price target of $60.75, an upside of 11.41% from Livanova's current stock price of $54.53.
Livanova stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Livanova, 0% have issued a Strong Buy rating, 75% have issued a Buy, 25% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Infusystem Holdings (NYSEMKT:INFU)
The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.
Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 29, which is 4 points higher than the healthcare sector average of 25. It passed 9 out of 33 due diligence checks and has average fundamentals. Infusystem Holdings has seen its stock return 52.34% over the past year, overperforming other healthcare stocks by 93 percentage points.
Infusystem Holdings has an average 1 year
price target of $12.00, an upside of 22.7% from Infusystem Holdings's current stock price of $9.78.
Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.